Lu YS - Search Results

1

Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.

Yeh KH, Lu YS, Hsu CH, Lin JF, Hsu C, Kuo SH, Li SJ, Cheng AL. Yeh KH, et al. Among authors: lu ys. Oncology. 2005;69(1):88-95. doi: 10.1159/000087304. Epub 2005 Aug 2. Oncology. 2005. PMID: 16088236 Clinical Trial.

2

Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.

Hsu C, Huang CS, Chao TY, Lu YS, Bu CF, Chen MM, Chang KJ, Cheng AL. Hsu C, et al. Among authors: lu ys. Cancer. 2002 Nov 15;95(10):2044-50. doi: 10.1002/cncr.10951. Cancer. 2002. PMID: 12412156 Free article. Clinical Trial.

3

A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.

Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, Yeh KH. Hsu CH, et al. Among authors: lu ys. Anticancer Res. 2002 Nov-Dec;22(6B):3621-7. Anticancer Res. 2002. PMID: 12552966 Clinical Trial.

4

High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma.

Yeh KH, Lu YS, Hsiao CH, Cheng AL. Yeh KH, et al. Among authors: lu ys. Anticancer Res. 2003 Nov-Dec;23(6D):5133-7. Anticancer Res. 2003. PMID: 14986591

5

Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.

Lu YS, Hsu C, Li CC, Kuo SH, Yeh KH, Yang CH, Hsu CH, Wu CY, Cheng AL. Lu YS, et al. Hepatogastroenterology. 2004 May-Jun;51(57):815-9. Hepatogastroenterology. 2004. PMID: 15143923 Clinical Trial.

6

Recent advances in the management of primary breast cancers.

Lu YS, Kuo SH, Huang CS. Lu YS, et al. J Formos Med Assoc. 2004 Aug;103(8):579-98. J Formos Med Assoc. 2004. PMID: 15340657 Review.

7

Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer.

Yeh KH, Lu YS, Hsu CH, Lin JF, Chao HJ, Huang TC, Chung CY, Chang CS, Yang CH, Cheng AL. Yeh KH, et al. Among authors: lu ys. Br J Cancer. 2005 Mar 28;92(6):1013-8. doi: 10.1038/sj.bjc.6602469. Br J Cancer. 2005. PMID: 15770209 Free PMC article. Clinical Trial.

8

Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients.

Su WP, Wen CC, Hsiung CA, Su IJ, Cheng AL, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu C, Hsu CH, Lu YS, Tien HF, Chao TY, Chen LT, Whang-Peng J, Chen PJ. Su WP, et al. Among authors: lu ys. World J Gastroenterol. 2005 Sep 14;11(34):5283-8. doi: 10.3748/wjg.v11.i34.5283. World J Gastroenterol. 2005. PMID: 16149133 Free PMC article.

9

Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors.

Lu YS, Lien HC, Yeh PY, Yeh KH, Kuo ML, Kuo SH, Cheng AL. Lu YS, et al. World J Gastroenterol. 2005 Oct 28;11(40):6373-80. doi: 10.3748/wjg.v11.i40.6373. World J Gastroenterol. 2005. PMID: 16419168 Free PMC article.

10

Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-{kappa}B activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa.

Lu YS, Yeh PY, Chuang SE, Gao M, Kuo ML, Cheng AL. Lu YS, et al. J Endocrinol. 2006 Feb;188(2):311-9. doi: 10.1677/joe.1.06453. J Endocrinol. 2006. PMID: 16461557

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

489 results

Search Page

Filters